Join to view full profile
333 Cedar St# 205New Haven, CT 06510
Phone+1 203-785-4095
Fax+1 203-785-4116
Dr. Malhotra is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2012 - 2015
MedStar Health/Georgetown-Washington Hospital CenterResidency, Internal Medicine, 2006 - 2009
Maulana Azad Medical CollegeClass of 2005
Certifications & Licensure
CA State Medical License 2022 - 2028
NJ State Medical License 2015 - 2027
CT State Medical License 2026 - 2026
NY State Medical License 2010 - 2026
DC State Medical License 2006 - 2009
PA State Medical License 2009 - 2009
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Patient Engagement Portal, Navigating Cancer, Inc., 2016-2017
- CMS Meaningful Use Stage 1 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2016-2017
Clinical Trials
- Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Start of enrollment: 2011 Nov 23
- First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors Start of enrollment: 2017 May 04
- Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy Start of enrollment: 2020 Apr 16
Publications & Presentations
PubMed
- The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care.Aritro Nath, Jyoti Malhotra, Isa Mambetsariev, Jeremy Fricke, Javier Arias-Romero
Cell Reports. Medicine. 2026-06-16 - The ADAPT learning cancer treatment system: ARPA-H's initiative to revolutionize cancer therapy.Andrea H Bild, Michelle C Sangar, Jasmine A McQuerry, Trey Ideker, Scott Kopetz
Cancer Cell. 2026-03-09 - 1 citationsA first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors.Gerald Falchook, Camila Braganca Xavier, David Van Veenhuyzen, Jyoti Malhotra, Saeed Sadeghi
NPJ Precision Oncology. 2026-02-28
Press Mentions
City of Hope Receives $23.7 Million Grant to Map Biomarkers of Treatment Resistance in Common Lung CancerJune 18th, 2025- City of Hope Awarded $23.7 Million to Map Biomarkers Linked to Treatment Resistance in Patients with Common Lung CancerJune 17th, 2025
- Should First-Line Dual Checkpoint Blockade Be Used for NSCLC with Specific Mutations?October 24th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
